[MGCC Perspectives] Design Innovations – Why Are They Important in the Furniture Industry
[New Sunday Times] You too could have an idea that generates millions
Bulletproofing Ideas?
“Beneath this mask there is more than flesh; beneath this mask there is an idea; and ideas are bulletproof,” said the masked vigilante in the movie “V for Vendetta” before snapping the neck of a corrupt politician. I was acting out the final fight sequence the other day (note to self: must get a life!), and as I was about to utter the above-mentioned line, I was intrigued by it. Could ideas really be protected? Can ideas be bulletproofed?
In this modern Information Age, ideas are held in higher regard than ever before. The global gold rush for new ideas and information, coupled with such limited supply, has led to huge corporations going to war with each other to secure monopoly of their ideas. Their weapon of choice is none other than stockpiles of Intellectual Property Rights (IPRs). The worldwide legal proceedings between Apple and Samsung are salient examples of an arms race of sorts where IPRs ranging from Patents to Trademarks, Copyrights to Industrial Designs are tossed into the fray.
[Malaysia SME] SMEs Going Abroad Urged To Register Trademarks
[Malaysia SME] Innovation in SMEs
[The Petri Dish] Technical Knowledge Database from Patents
[Asia IP] Much Ado about Nutting: Nutella Vs. Nutello
[Business Today] Ignite Your Senses + Colour Wars
Amendments To Diovan Patent Claims Allowed
A recent decision in the High Court of Singapore involved yet another dispute in the pharmaceutical industry between an innovator giant and a generic manufacturer. This time, the case refers to a patent litigation battle between Switzerland-based Novartis and its exclusive licensee in Singapore (the Plaintiffs), and Ranbaxy (M) Sdn Bhd (the Defendant).
On the facts, the Defendant had made an application to the Health Sciences Authority on product licences for the product, Starval, to be imported into the Singaporean market.Starval is a generic version of the Plaintiffs’ product, Diovan, a blockbuster drug for treating hypertension. Novartis then brought an action towards the Defendant when the application was made known to them via notice, asserting that the Defendant’s product could possibly infringe the Diovan patent.
- « Previous Page
- 1
- …
- 64
- 65
- 66
- 67
- 68
- …
- 110
- Next Page »